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Role of Eosinophils in Inflammatory Bowel and
Gastrointestinal Diseases
Samantha A. Woodruff, Joanne C. Masterson, Sophie Fillon,
Zachary D. Robinson, and Glenn T. Furuta
ABSTRACT
Inflammatory bowel diseases (IBD) are characterized by the invasion of
leukocytes into the intestinal mucosa. However, a mixed inflammatory
picture is observed that includes neutrophils, lymphocytes, monocytes,
and eosinophils. To this day, the role of eosinophils in health and in disease
remains unclear. Investigations into their function stem primarily from
allergic diseases, asthma, and parasitic infections. This makes it even more
difficult to discern a role for the fascinating eosinophil in IBDs because,
unlike the lung or the skin, eosinophils reside in normal intestinal mucosa
and increase in disease states; consequently, an intricate system must
regulate their migration and numbers. These granulocytes are equipped
with the machinery to participate in gastrointestinal (GI) inflammation and
in the susceptible microenvironment, they may initiate or perpetuate an
inflammatory response. A significant body of literature characterizes eosi-
nophils present in the GI microenvironment where they have the potential to
interact with other resident cells, thus promoting intestinal remodeling,
mucus production, epithelial barrier, cytokine production, angiogenesis, and
neuropeptide release. A number of lines of evidence support both potential
beneficial and deleterious roles of eosinophils in the gut. Although studies
from the gut and other mucosal organs suggest eosinophils affect mucosal GI
inflammation, definitive roles for eosinophils in IBDs await discovery.
Key Words: Crohn disease, eosinophil, inflammatory bowel disease,
ulcerative colitis
(JPGN 2011;52: 650–661)
E nigmatic eosinophils continue to intrigue clinicians and scien-tists alike. Although their presence in mucosal microenviron-
ments traditionally characterizes allergic diseases, their role in other
diseases (rheumatologic, infectious, idiopathic inflammatory)
remains unknown. Equally confounding is that, unlike the lung
or skin, eosinophils normally reside in intestinal mucosa, suggesting
that they play a role in gastrointestinal (GI) health. Despite this
knowledge, advancement on the understanding of their exact role in
GI health and disease remains limited. With this in mind, we review
basic, translational, and clinical studies that focus on proposed
functions of eosinophils in the intestinal mucosa, provide an over-
view of eosinophil trafficking, and speculate as to the role of these
intriguing cells in the intestinal microenvironment as they relate to
inflammatory bowel diseases (IBDs).
ARE EOSINOPHILS EQUIPPED WITH
MACHINERY TO PARTICIPATE IN GI
INFLAMMATION?
Eosinophils are armed with the ability to synthesize and
release a number of molecules that reflect their potential physio-
logical diversity and biological influence (Table 1). In the suscept-
ible microenvironment, they may initiate or perpetuate an
inflammatory response.
Granule Proteins
Eosinophils are best identified by their abundance of granular
proteins, also referred to as eosinophil-derived granule proteins
(EDGPs). There are at least 5 proteins secreted from the eosinophil
granule including eosinophil peroxidase (EPO), eosinophilic
cationic protein (ECP), eosinophil-derived neurotoxin (EDN; eosi-
nophil protein X, or EPX), major basic protein (MBP), and Charcot-
Leyden crystal protein. MBP is one of the most abundant proteins
produced by eosinophils, and is found as 2 different homologues
(MBP1 and MBP2). MBP1 is also produced at much lower levels in
basophils; however, MBP2 is eosinophil specific (1,2). ECP and
EDN are both ribonucleases and both function to protect the host
from infections, mainly, it is thought, through pore formation in
pathogens (3–5). EPO is 68% homologous to its neutrophil counter-
part myeloperoxidase and functions similarly in antimicrobial or
antiviral roles in addition to contributing to superoxide production
(6,7). Charcot-Leyden crystal is found in both eosinophils and
basophils (8); however, traditionally it has been associated with
conditions characterized by eosinophilia, including asthma, aller-
gies, and parasite infection. Indeed in the 1970s, the presence of
EDGPs following eosinophil degranulation was predominantly
noted at sites of parasitic infection and was thought to represent
evidence of antiparasitic activity. These highly charged cationic
proteins create pores in cellular membranes resulting in parasite
death and host protection (9,10). In mice, increases in parasite
burden following thoracic filarial parasitic infection was observed
in strains deficient in either EPO or MBP granule proteins (11);
however, human EPO deficiency is a rarely reported finding and has
no known clinically associated symptoms (12). Thus, eosinophils
were thought to act in a protective manner, defending the host from
invading pathogens and potential disease.
Although early studies suggested that extracellular depo-
sition of EDGPs represented an important host defense mechanism,
present-day studies have also focused on the contribution of EDGPs
and other eosinophil-derived factors to disease pathogenesis and
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chronicity, often in the absence of known pathogenic infection.
Extensive eosinophil degranulation is often associated with fibrosis
in hypereosinophilic syndrome, eosinophilic esophagitis (EoE),
IBDs, asthma, and eczema (13–16). EDGPs are known to activate
inflammatory mediator release from basophils and mast cells (17–
19). Bischoff et al (20) identified the altered presence of eosinophils
and mast cell degranulation products in a morphometric study of
patients with IBD compared with normal controls.
Cytokines
Eosinophils are classically associated with a T helper 2 cell
(TH2) cytokine profile including interleukin (IL)-4, IL-5, IL-10,
and IL-13 (Table 1). IL-5 is critical for eosinophil growth,
chemotaxis, and activation, whereas synergistic functions
between eotaxin and IL-13 or eotaxin and IL-5 act as an eosinophil
chemoattractant mechanism supporting a role for perpetuating eosi-
nophilic inflammation (21,22). Their ability to produce this classical
repertoire of TH2 cytokines supports their role in allergic-type
responses. In this regard, eosinophils express a number of cytokine
receptors on their surfaces (23) and, therefore, may respond to their
localmicroenvironment.Autocrine activities of IL-3 and granulocyte
macrophage-colony-stimulating factor (GM-CSF) on tissue residing
eosinophils suggest that theymayplayanautoregulatory role inwhich
eosinophils could control their own maturation and antiapoptotic
mechanisms during disease processes. These cytokines in addition
to IL-5promoteeosinophil survival followingrecruitment to inflamed
sites.
In contrast to this association with TH2–cytokine–mediated
diseases, eosinophils also have the capacity to synthesize and
secrete TH1 cytokines in both health and disease (24). Tumor
necrosis factor-alpha (TNF-a), the key cytokine in Crohn disease
(CD), has been associated with recruitment of eosinophils in IBD
(25). Interestingly and in contrast to their roles in other cell types,
activation of the TNF receptor 1 and TNF-related apoptosis-indu-
cing ligand in eosinophils is associated with prolonged eosinophil
survival (26,27).
The TH2 cytokine IL-13 is a pivotal player driving the major
pathologies associated with asthma, regulating eosinophil recruit-
ment (chemokine induction), mucus secretion (cell differentiation),
and airway hyperresponsiveness (smooth muscle activation) (28).
During appropriate inflammatory conditions eosinophils produce
functional IL-13 protein (29). Eosinophils are also potent sources
of the immunoregulatory, profibrotic cytokine transforming growth
factor-b (TGF-b). TGF-b is implicated in tissue remodeling in
various diseases including pulmonary and esophageal diseases
(30). TGF-b is the prototypical ligand for the TGF superfamily of
cytokines and growth factors. This family of growth factors is
implicated in various downstream functions including control of
proliferation and differentiation processes, inflammation, and, most
notably, fibrosis. Eosinophils also secrete the anti-inflammatory
agents IL-10 and indoleamine 2,3-dioxygenase, all important
mediators for the immunoregulation of proinflammatory TH1-cell
activity. Although a strong case for the proinflammatory role of
eosinophils exists, there is a growing body of evidence to support a
potential regulatory role for eosinophils in mucosal microenviron-
ments (31). For instance, in certain murine allergic pulmonary
models, eosinophils are required for the recruitment of effector T
cells and the resulting pulmonary pathology associated with murine
ovalbumin (OVA)–induced airway hyperresponsiveness (32,33).
Jacobsen et al elegantly demonstrated the necessity for pulmonary
eosinophilia for the successful recruitment of effector T cells and for
the establishment of a TH2 cytokine environment in this murine
pulmonary allergymodel (33). In amurinemodel of Schistosoma egg
induction of TH2-associated inflammation, Sabin et al (34) demon-
strated the necessity for eosinophils in the early production of the
TH2-driving cytokine IL-4. In the absence of eosinophil recruitment
mediated bymast cells and IL-5, there is an ablation of this critical IL-
4 production. The role of eosinophils in antiparasitic immunity
remains under investigation. A number of infection models in mice
chemically or genetically deficient in eosinophil responses found no
specific role for the eosinophil (23). In IBD, research suggests an
association between elevated eosinophil activation and relapsing
disease activity,whereasothers suggest a reparative role as eosinophil
levels rise during the remission of intestinal inflammation (25,35).
Eosinophils also produce potentially anti-inflammatory agents such
as arylsulfatase B, histaminases, and phospholipase D, adding to this
suggestion (23).
In addition to cytokines, eosinophils secrete chemokines
such as eotaxins, RANTES, and macrophage inflammatory
protein-a (MIP-1a) (5,36) (Table 1). Eotaxins (1, 2, 3) are
potent eosinophil chemoattractants, and their secretion by eosino-
phils demonstrates their ability to initiate/perpetuate an inflamma-
tory response (37). Eotaxin attracts eosinophils via interaction with
the C-C chemokine receptor 3 (CCR3) receptor, which is expressed
almost exclusively by eosinophils (38,39). RANTES stimulates
both eosinophil and neutrophil recruitment (40). In contrast,
MIP-1 a is important primarily in neutrophil trafficking (41). Thus,
eosinophils secrete chemokines involved in their own recruitment,
as well as in other leukocyte recruitment and activation. In this light,
eosinophils play an important role in mediating the establishment
TABLE 1. Eosinophil-derived products with potential targets of action
Eosinophil products Target cells
IL-3, IL-5, GM-CSF, eotaxins, EDGPs Autocrine eosinophil activity
TH1: IL-2, IL-6, IL-12, TNF-a, IFN-g Lymphocytes
TH2: IL-2, IL,4 IL-5, IL-10, IL-13, leukotrienes
IL-1, IL-3, IL-4, IL-5, IL-9, IL-13, TNF-a, GM-CSF, leukotrienes, prostaglandins, EDGPs Mast cells
IL-1, IL-4, IL-5, IL-6, IL-13, TGF-b, GM-CSF, leukotrienes, eotaxins, EDGPs Epithelial cells
IL-1, IL-6, TGF-b, leukotrienes, eotaxins, EDGPs Endothelial cells
Eotaxins, neurotrophic growth factors, substance P, EDGPs Neurons
IL-1, IL-5, IL-13, TGF-b, leukotrienes, eotaxins, EDGPs Smooth muscle cells
IL-1, IL-4, IL-13, TGF-b, eotaxins, EDGPs Fibroblasts
TGF-a Goblet cells
EDGP¼ eosinophil-derived granule protein; GM-CSF¼ granulocyte macrophage-colony-stimulating factor; IFN¼ interferon; IL¼ interleukin;
TGF¼ transforming growth factor; TH¼T helper cell; TNF¼ tumor necrosis factor.
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and maintenance of the local immune microenvironment following
activation.
Lipid Mediators
Eosinophils secrete lipid mediators including leukotrienes
and platelet-activating factor. In addition, eosinophils express
receptors for leukotrienes and prostaglandins (Table 1). These
products are generally considered proinflammatory because they
increase leukocyte trafficking, endothelial adhesion, smoothmuscle
contraction, vascular permeability, and mucus secretion (5). The
role of lipid mediators in asthma and allergic inflammation has been
well defined as they cause bronchoconstriction, mucus hypersecre-
tion, and bronchial hyperresponsiveness. Vieira-de-Abreu et al (42)
demonstrated increased in vivo formation of lipid bodies and
leukotrienes within infiltrating eosinophils in a mouse model
of asthma.
HOW DO EOSINOPHILS TRAVEL TO GI
MUCOSAL SURFACES?
Because eosinophils normally reside in the GI tract and
increase in disease states, an intricate system must regulate their
migration and numbers.
Growth and Development
Hematopoietic stem cells differentiate into myeloid lineage–
specific progenitor cells, which give rise to a common precursor cell
of both basophil and eosinophil cells in the bone marrow. Eosino-
phil specification is regulated in this common precursor cell by
the control of transcription factors GATA-1, PU.1, and c/EBP. IL-3,
IL-5, and GM-CSF play important roles in the development of
eosinophils. Eosinophil progenitor cells express the cytokine-
specific alpha receptors for each of these cytokines along with
the beta-receptor unit shared by all 3. Under the influence of these
cytokines in concert with temporal regulation of the transcription
factors mentioned above, eosinophils mature and are ready for exit
from the bone marrow. The IL-5 cytokine is the most specific of
these eosinophilopoietins for eosinophil development, and its
actions are essential for the migration of eosinophils into the
bloodstream, where they reside for approximately 1 week (5). Mice
deficient in IL-5 lack appropriate eosinophil responses during
inflammatory states with deficiency in mounting robust eosinophil
responses (43,44), whereas transgenic mice engineered to over-
produce IL-5 have profound eosinophilia (45). However, other cells
are also equipped to respond to this cytokine. Detailed descriptions
of the eosinophil life cycle are available (5).
Migration to Intestinal Mucosa
Eosinophil Migration to Intestinal Mucosal
Surfaces
Under normal conditions, the vast majority of eosinophils
reside in the GI mucosa, and during disease states, these levels
increase (5). Understanding signals that drive intestinal eosinophilia
is particularly important because unlike the lung and skin, eosinophils
are normal inhabitants of the GI mucosa. Mechanistic studies elu-
cidating how eosinophils home to GI surfaces have focused on the
role of eotaxin and IL-5. Eotaxin null mice lack intestinal and thymic
eosinophils, whereas the induction of allergic airway disease in these
mice results in a diminished pulmonary eosinophilia (46,47).
Eosinophils express specific adhesionmolecules that allow for
their migration out of the periphery and across the endothelium in
response to chemoattractants such as eotaxins— a process known as
extravasation. This extravasation process is mediated by similar
molecules andprocesses thatmediate all leukocytemigration, rolling,
adhesion, and transmigration. The exact mechanisms by which
eosinophils are recruited to areas of inflammation are beginning to
be unraveled. Tissue specificity for eosinophil recruitment is thought
to be mediated by the various chemokines, selectins, integrins, and
adhesionmolecules and their receptors, both on the eosinophil and on
the vascular endothelium. Expression of these molecules may be
controlled in a microenvironmentally specific manner. For example,
Brandt et al (48) found an essential role for b7-integrin in the
recruitment of eosinophils to small intestinal inflammation, but found
no role for this integrin’s expression for eosinophil recruitment to
the lung.
Eosinophils constitutively express L-selectin and, in addition,
use both E- and P-selectin machinery to slow down and tether to
endothelial cells (49–51). P-selectin glycoprotein ligand (PSGL-1)
and sialyl-Lewis x, the ligands for endothelial E- and P-selectin, are
expressed on eosinophils (52). The recruitment of eosinophils toward
peritoneal ragweed sensitization and challenge models in mice
deficient in L-, E-, or P-selectin or deficient in combinations of these
selectins found a role for each of these molecules in eosinophil
adhesion to the endothelium. The authors of this work pointed to a
particularly important role for P-selectin. However, they also high-
lighted the potential for other nonselectin-dependent mechanisms of
eosinophil recruitment resulting from the continued recruitment of
eosinophils in mice deficient in all 3 selectins (53). Indeed, dextran
sodium sulfate (DSS) colitis induced in L-selectin-specific–deficient
mice revealed no role for this selectin in this model of acute large
intestinal inflammation (54).
Once tethered to the cytokine-activated endothelium, eosi-
nophils roll, spread, and transmigrate between endothelial cells and
across the endothelial basement membrane. There, eosinophils
make their way through the extracellular matrix to the source of
the original chemotaxin and respond to inflammation by potential
activation and degranulation. This migration process is controlled
by integrins and their receptive endothelial or matrix protein
receptors. Eosinophils have overlapping recruitment pathways to
mast cells, and basophils, however, distinctively express a large
number of adhesion molecules and receptors that specifically
control their transmigration, namely a3, a4, a5, a6, aD, aL,
aM, aX, and b1, b2, and b7 integrins (55). Eosinophils, in addition,
express certain cell adhesion molecules (CAMs) that bind these
integrins. Very late antigen (VLA-4) and lymphocyte function–
associated antigen (LFA-1) on the eosinophil surface interact with
endothelial vascular cell adhesion molecule (VCAM-1) and inter-
cellular adhesion molecule 1 (ICAM-1) in a process regulated by
eotaxins. Inhibition of these ligands disrupts the migration of
eosinophils into the tissue in experimental models and clinical
trials, emphasizing their importance as components in the eosino-
phil inflammatory response (21,56).
Brandt et al and Forbes et al identified specific adhesion
molecules necessary for eosinophil recruitment to the small and
large intestinal mucosa. Small intestinal eosinophil recruitment
relies on MadCAM-1/a4b7 integrin interactions; however, colonic
eosinophil migration relies onb2 integrin molecules (48,54,57). For
instance, b7-integrin knockout mice developed less small bowel
inflammation compared with wild-type controls in a model of
allergic disease (48). Mice exhibited increased circulating eosino-
phils, indicating no role for this integrin in bone marrow exit and
vascular entry. This deficiency is only apparent during inflam-
mation because there is no baseline deficiency in eosinophil
presence in the small intestine during homeostasis in b7-integ-
rin–deficient mice. Another method of tissue-specific homing of
eosinophils involves the differential regulation of the chemokines
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C-C chemokine ligand 25 (CCL25) (TECK) in the small intestine
and CCL28 (MEC) in the large intestine (40,58). The receptors for
these chemokines, CCR9 and CCR3, have been demonstrated on
the surface of eosinophils, as has the eosinophil responsiveness in
culture conditions (59,60).
Using ICAM-1 null mice and ICAM neutralizing antibodies
in a DSS colitis model, Forbes et al (54) demonstrated the b2-
integrin/ICAM-1 dependency of colonic eosinophilic inflam-
mation. In contrast, DSS colitis in a b7-integrin knockout mouse
and mice treated with a4-integrin inhibitory antibodies showed no
change in the level of eosinophil recruitment to the colon.
Eosinophils use VLA-4 (a4b1) and VLA-6 (a6b1) to inter-
act with basement membrane and extracellular matrix proteins, such
as laminin, collagen, and fibronectin to traverse the basement
membrane and travel through the lamina propria (61,62). This
binding leads to eosinophil priming, and following exposure to
inflammatory cytokines, eosinophils become activated and may
degranulate upon appropriate stimulation. In the absence of these
tissue-recruitment signals or the lack of survival signals such as
GM-CSF, IL-5, or TNF, eosinophils will undergo apoptosis (21).
Taken together, these findings suggest a variety of regulatory
mechanisms for the different GI microenvironments that may
ultimately affect future therapeutic interventions.
Esophageal Mucosa
Normal esophageal mucosa does not contain eosinophils.
Eosinophils increase in squamous epithelia of the esophageal
mucosa during gastroesophageal reflux disease (GERD) and
EoE, but the characteristic numbers and associated histological
features of each disease are only now being addressed. For instance,
GERD is traditionally associated with a small number of eosino-
phils in the distal squamous epithelial surface, but recent evidence
demonstrates that large numbers (>15 eosinophils/hpf) can be
found in both the proximal and distal epithelium of children and
adults with GERD (63,64). During the last decade, an emerging
body of evidence shows that eosinophils also increase in EoE (65).
EoE is a clinicopathological disease characterized by upper intes-
tinal symptoms seen in association with >15 eosinophils/hpf in
which GERD and other diseases have been ruled out. Gastric and
duodenal biopsies must also be normal.
The mechanisms leading to esophageal eosinophilia have
been addressed in several human genetic studies together with a
number of murine models. An important study of human esophageal
biopsies by Blanchard et al (66) identified a unique transcript
signature that reliably identified patients with EoE. Of these genes,
eotaxin 3 was the most upregulated gene. Further studies confirmed
this association and identified IL-13 as a potent regulator of eotaxin
3 in esophageal biopsies and isolated epithelial cells (67). Thus,
these studies define a role for eotaxin 3 in certain patients with EoE.
A more recent study (68) of genome-wide associations identified a
link between certain patients with EoE and variants at the 5q22 loci.
This and future studies will help elucidate the mechanisms by which
eosinophils are recruited in individuals and may provide more
guidance in the management of this disease.
Mice sensitized to and challenged with the ubiquitous aero-
allergen, Aspergillus fumigatus, develop significant IL-5–dependent
esophageal eosinophilia (69,70). Intratracheal administration of IL-
13 promotes eosinophil recruitment to the esophagus in mice;
however, this recruitment is ablated in mice genetically deficient
in IL-5 (71). Pretreatment with an IL-13–blocking antibody effec-
tively diminished eosinophilia in the same model system (72).
Recently published work has additionally pointed to the indoor
allergens, house dust mite and cockroach antigens, as potent inducers
of experimental eosophageal eosinophilia. In the present study,
authors indicate an increase in IL-4 and IL-13 in response to antigen
exposure, whereas administration of antigen to Eotaxin1/2 double
knockout, CCR3– or IL-5–deficient mice abrogated eosinophil
recruitment, indicating an essential role for these molecules in this
allergen-induced model of esophageal eosinophilia (73). Together,
these studies suggest that an exogenous allergen leads to esophageal
eosinophilia that is dependent on TH2-type cytokines, IL-4, IL-5, and
IL-13. Despite these studies indicating the essential role for IL-5 in
murinemodels, recent open-label trials using anti-IL-5 therapieswere
found to be effective in only a small number of patients (74,75).
Gastric, Small Intestinal, and Colonic Mucosa
Eosinophils localize to the GI tract during perinatal devel-
opment in an eotaxin- and IL-5–dependent manner (22). Whereas
eosinophils are present in the lamina propria of wild-type, 19-day-
old mouse embryos, their numbers in intestinal mucosa are signifi-
cantly diminished in IL-5–deficient mice and eotaxin-deficient
mice (22). Interestingly, the same study found no difference in
the homeostatic levels of eosinophils in jejunal tissue of GM-CSF–
deficient mice. Further investigation found no difference in the
number of eosinophils in the bone marrow but decreased levels in
circulation, indicating a critical role for these cytokines in exit of
eosinophils from the bone marrow. Epithelial overexpression of IL-
5 and eotaxin leads to significantly increased numbers of intestinal
eosinophils compared with control mice (57). In contrast, studies in
isolated eotaxin deficiency show an absence of eosinophils in the
intestine, even in the presence of high levels of IL-5, maintaining
the essential role for eotaxins in the recruitment of eosinophils into
the GI tract (22,57). Finally, mice sensitized by intraperitoneal
injection with OVA and later challenged with orally administered
OVA develop significant eosinophilic GI inflammation. However,
mice deficient in eotaxin under the same conditions have impaired
eosinophil recruitment to intestinal tissues and are protected from
weight loss and gastromegaly (76). All of these results further
support the critical role of IL-5 in the development of eosinophils in
the bone marrow; however, tissue eosinophilia is dependent on
eotaxin. Thus, these proteins work in concert to induce an efficient
eosinophil response in appropriate conditions.
WHAT ARE THE FUNCTIONAL ROLES OF
EOSINOPHILS?
A number of lines of evidence support both potential
beneficial and deleterious roles for eosinophils in the gut (Fig. 1).
Potential Beneficial Aspects of Eosinophilia
Eosinophils likely benefit human health, but at the present
time, these roles are still speculative. Circumstantial evidence for a
supportive role stems from their phylogeny that dates back to
chordates. Eosinophils are present in normal mammalian mucosa,
and genes encoding EDGPs are evolutionarily conserved between
numerous species. Interestingly, eosinophils accumulate primarily
at body surfaces that border the external environment, such as the
GI mucosa, supporting a potential role in host defense (77).
Antiparasitic
Eosinophils have been classically described as antiparasitic
leukocytes. Peripheral eosinophilia increases during helminth infec-
tion and eosinophils migrate to areas of parasitic infection with
terminal endpoints of degranulation at sites of parasitic infiltration
(10,78). Epidemiological studies correlate peripheral eosinophilia
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with protection against schistosomal infections in Africa. Proposed
mechanisms for this response include the ability of EDGPs to induce
cell membrane pore formation and mediate antibody- and/or comp-
lement-dependent cellular toxicity to parasites (79).
Despite these studies that suggest a role for eosinophils in
helminth infection, data from murine models are less certain.
Reduction of IL-5, either by genetic manipulation or by antibody
depletion, leads to diminished eosinophilia and, in certain infec-
tions, more severe parasitic infection compared with mice that have
a full complement of eosinophils. For example, IL-5 null mice
infected with the nematode Strongyloides ratti show increased
worm burden, tissue damage, and parasite fecundity. However,
infection with the trematode Fasciola hepatica does not lead to
phenotypic differences in IL-5 null mice compared with wild type
(79,80). In addition, mice depleted of eosinophils with the use of
anti–IL-5 antibody do not show alterations in Trichinella infection
compared with untreated mice (81). Finally, IL-5 transgenic mice
with marked eosinophilia have no protection from Trichinella
spiralis infection (82). It is likely that these differences can be
attributed to redundancy of effector immune responses to specific
pathogens and differences in the animal model that was used (80).
Role in Cancer
Recent studies suggest that, in some circumstances, eosino-
phils possess antineoplastic properties. For instance, eosinophils are
associated with necrotic areas of tumors and within the tumor
pseudocapsules. Peripheral eosinophilia is associated with
improved prognosis in GI and head and neck cancers, but a poorer
prognosis in oral squamous cell carcinoma. Certain forms of human
cancer treatments that include cytokines IL-2, IL-4, and GM-CSF
promote eosinophilia (83).
Murine studies support a role for eosinophils in decreasing
tumor burden. For instance, in a murine model of cancer, malignant
cells were transfected to constitutively overproduce IL-4. This leads
to tissue eosinophilia at the site of tumors, decreased tumor burden,
and improved survival (84). In another murine model, melanoma
cells were transfected to express ovalbumin and injected into mice.
OVA-specific TH1 or TH2 cells were generated and injected into the
mice, and lung metastases were measured 18 to 20 days after tumor
challenge. Lung metastases regressed in the mice injected with TH2
but not TH1 CD4þ cells. Regression of lung metastases was
associated with the influx of eosinophils into the tumor sites,
and degranulating eosinophils were detected at regressing tumor
sites. Eosinophil recruitment and tumor regression was not noted in
eotaxin-deficient mice, implicating eotaxin as a key molecule in the
recruitment of eosinophils to tumor sites (85). In mice completely
void of eosinophils, fibrosarcoma tumor burden is significantly
enhanced (86). Finally, recent speculation suggests that eosinophils
can respond and traffic to damage-associated molecular pattern
molecules (83).
In contrast, eosinophils may promote the growth of certain
tumors. For instance, in a hamster model of squamous cell
FIGURE 1. Proposed roles for eosinophils within the intestinal mucosa. Based on basic, translational, and clinical studies derived
from other organs and the gastrointestinal tract, this figure presents potential mechanisms for eosinophils to interact with resident
intestinal cells. Each of these complex and dynamic relationships is described in detail in the body of this review.
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carcinoma, the administration of anti–IL-5 antibody completely
obliterated tumor-associated tissue eosinophilia and subsequently
decreased tumor burden and delayed the onset of cancer develop-
ment (87).
Antiviral
As previously noted, eosinophil granule proteins demon-
strate antiviral activities. ECP and EDN are ribonucleases with
antiviral activity (88). Eosinophils express Toll-like receptors
(TLR)-3, TLR-7, and TLR-9, which recognize dsRNA, ssRNA,
and dsDNA, respectively (89,90). Activation of the TLRs generates
interferon-beta, thus initiating antiviral host responses (4). Also, in a
murine model of respiratory syncytial virus (RSV) infection, IL-5
transgenic mice that harbor profound peripheral eosinophilia show
accelerated virus clearance and decreased airway hyperreactivity
(4). Transfer of eosinophils, but not IL-5 alone, into RSV-infected
wild-type mice leads to accelerated viral clearance and diminished
airway hyperreactivity supporting eosinophil specificity of this
response. Finally, eosinophil-deficient mice have significantly
delayed RSV clearance (4).
Antibacterial
Traditional studies of innate effector cells providing immu-
nity to bacteria have focused on the roles of neutrophils and
macrophages. The contribution of eosinophils has been understu-
died and overlooked. Lehrer et al (91) provided early evidence for
the antibacterial role of the eosinophil granule proteins ECP and
MBP in vitro. However, 2 recent publications have rehighlighted
the potential importance of eosinophils in challenging bacterial
infections. Mice deficient in eosinophils had a significant increase
in the colony-forming units of Pseudomonas aeruginosa bacteria
following infection of mouse peritoneal cavities, and the induction
of Pseudomonas peritonitis. This bacterial burden was abrogated in
mice transgenically engineered to have profound eosinophilia (IL-5
transgenic mice) or in mice treated with eosinophil granules
following infection (92). Yousefi et al (93) described a previously
undetected process by which eosinophils release their mitochon-
drial DNA in a catapult-like fashion, without subsequent death of
the eosinophil, which leads to extracellular bacterial death. This
release was detected in response to lipopolysaccharide from Gram-
negative bacteria and showed successful killing of Escherichia coli
in a DNA-dependent fashion in vitro. In support of this antibacterial
role for eosinophils, in vivo studies using the mouse bacterial
intestinal infection model cecal ligation puncture in mice with high
levels of eosinophilia (IL-5 transgenic) found significant improve-
ment in survival and significant reduction in circulating bacterial
burden. Although these studies call attention to the beneficial role of
eosinophils in fighting bacterial infections, early reports suggested a
reduction in circulating eosinophils during the acute phase in
bacterial infections in patients (94). It, however, remains possible
that eosinophils have been recruited to the tissue site of infection
and may not be detectable in the circulation. This has never been
systematically studied, thus leaving unanswered the etiology of this
reduction and the role of the eosinophil in these infections.
Antigen Presentation
Wang et al (95) provide evidence supporting the eosinophil’s
role in antigen presentation. Isolated splenic eosinophils, free from
antigen-presenting cells, were cultured with GM-CSF and shown to
express major histocompatibility complex class II and other co-
stimulatory molecules. Eosinophils were then incubated with
OVA and transferred into the lung intratracheally. Exposure of
eosinophils to OVA-specific CD4þ T cells led to eosinophil pro-
liferation, cytokine secretion, and cell surface activation. These
studies provide supportive evidence that eosinophils may process
antigen in the lung lumen and function as antigen-presenting cells to
CD4þ lymphocytes (95). In another study, Shi et al (96) provided
morphological evidence of this process. Following airway challenge,
eosinophils were isolated from the airways or the peritoneal cavities
of IL-5 transgenic mice and fluorescently labeled ex vivo. Labeled
cells were reinstilled into the trachea and were found to home to
lymph nodes in an eotaxin-independent manner. Labeled eosinophils
expressed major histocompatibility complex class II and co-stimu-
latory CD80 and CD86 proteins and functioned in vitro as CD80- and
CD86-dependent, antigen-specific, antigen-presenting cells.
Innate Mechanisms of Defense
A potential mechanism for eosinophils to protect against
microbial invasion is through the stimulation of mucus production.
In the lung, eosinophils are associated with induction of mucus
production. Exposure of human airway epithelial cells to super-
natants derived from activated eosinophils leads to increased mucin
production through eosinophil release of TGF-a and activation of
epidermal growth factor receptor (EGFR) (97). Rhinopulmonary
epithelia associated with mucosal eosinophils have goblet cell
hyperplasia and metaplasia, indicative of accelerated mucus pro-
duction (98). Finally, in OVA-induced airway eosinophilic inflam-
mation, use of gefinitib, an EGFR inhibitor, or CCR3 monoclonal
antibody reduced eosinophil recruitment to the murine lung and
mucus production (99,100).
Potential Deleterious Aspects of Eosinophilia
Eosinophils also have been implicated as pathogenic effector
cells in asthma, atopy, eczema, infection (viral, bacterial, or para-
sitic), malignancy, EoE, GERD, IBD, allergic colitis of infancy,
celiac disease, vasculitis, connective tissue diseases, and hypereo-
sinophilic syndrome as reviewed previously (101). Much evidence
supporting a pathological role for eosinophils is derived from
morphological and association studies in which eosinophils and
their products are present in diseased tissue. Below we highlight the
potential pathogenic interactions of eosinophils with resident and
recruited cells of mucosal surfaces (Fig. 1).
Epithelium
Eosinophils are the predominant inflammatory cells found in
the airway epithelium in asthma. Bronchoalveolar lavage fluid from
asthmatics contains increased numbers of eosinophils and levels of
MBP. Early studies have shown MBP to be toxic to lung epithelia,
leading to increased airway epithelial permeability in vitro.
Although other eosinophil products are known to promote epithelial
proliferation (102), Pegorier et al (103) demonstrated that lung
epithelial cells exposed in culture to MBP or EPO showed a
significant increase in TGF-a, TGF-b1, EGFR, platelet-derived
growth factor-b, and tenascin mRNA levels.
Smooth Muscle Cells, Fibroblasts, and Nerves
The application of MBP to airway smooth muscle leads to
contraction and enhancement of muscle reactivity to acetylcholine
and histamine, findings that may explain the contribution of eosi-
nophils to airway hyperreactivity (5,56). Ablation of IL-5 in murine
models of asthma leads to decreased eosinophil recruitment to the
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airway, attenuated airway hyperreactivity, and diminished lung
damage (44). The most compelling evidence implicating eosino-
phils in the pathogenesis of asthma comes from the PHIL mouse, a
genetically engineered mouse that lacks eosinophils. Airway resist-
ance after methacholine challenge is significantly diminished in
PHIL compared with wild type, supporting a role for eosinophils in
airway dysfunction (104).
Eosinophils may also participate in tissue remodeling. For
example, ex vivo modeling of the human airway revealed that the
addition of activated eosinophils to a matrix of fibroblasts and
bronchial epithelial cells leads to a significant increase in epithelial
thickness (102). Gomes et al (14) revealed that coculture of eosino-
phils with fibroblasts induces fibroblast IL-6 and fibronectin pro-
duction. In further studies, eosinophil-derived IL-1a andTGF-bwere
shown to participate in this response, thus promoting a role for
eosinophils in modulating extracellular matrices. Studies examining
esophageal biopsies from patients with EoE associate eosinophils
with tissue remodeling (30). At endoscopy, some patients with EoE
demonstrate evidence of remodeling and fibrosis with the presence of
isolated strictures, long segment narrowing, or esophageal fragility
(16,105). Histological staining of the affected subepithelial layer
from patients with EoE reveals increased collagen deposition and
increasedTGF-b expression comparedwith patientswithGERDand
healthy controls (16,30). One of the complexities of intestinal eosi-
nophilia is the lack of reliable clinical outcomemeasures. Although a
number of studies provide circumstantial evidence for a role of
eosinophils in esophageal remodeling and fibrosis, the correlation
of fibrosis, eosinophilia, and symptoms remains variable.
Eosinophils have direct cell-to-cell contact with both airway
neurons in asthma (106) and damaged neurons of the GI tract in IBD
(76,106,107); however, the meaning of this interaction remains
uncertain. Kingham et al (108) demonstrated that upon coculture
with eosinophils, guinea pig parasympathetic nerves undergo dose-
dependent shortening. In addition, neuron differentiation is inhib-
ited by eosinophils or MBP in a dose-dependent manner. Eosino-
phils may also alter nerve remodeling. MBP inducedM2muscarinic
receptor expression on cholinergic nerves and reduction in intra-
cellular acetylcholine content in vitro (109). A recent review by
Raap and Wardlaw (110) rehighlighted the reciprocal interactions
between eosinophils and peripheral nerve cells. In this review they
emphasize a number of neuromediator receptors functionally
expressed on eosinophils leading to cytokine and granule protein
release. The effects of granule proteins on neuron function and
viability are addressed (eg, the in vitro neurotoxic activities of EDN
and ECP). In addition, the potential indirect interactions between
neuropeptides, mast cells, and eosinophils are discussed.
Mast Cells
A number of groups have characterized the influence of
eosinophils and EDGPs on mast cells. Zheutlin et al (111) showed
that rat mast cells significantly increase histamine release in
response to MBP and ECP, but not EDN. MBP induced histamine
release, arachidonic acid synthesis, and TNF-a release from murine
mast cells with a connective tissue phenotype (112). In contrast,
Okayama et al (113) showed that MBP, EPO, EDN, and ECP do not
stimulate histamine release from cultured human skin mast cells.
Taken together, these studies emphasize the complex and variable
role eosinophils may play on mast cell function depending on
the microenvironment.
DO EOSINOPHILS PLAY A ROLE IN IBD?
GI tissues affected by IBD demonstrate evidence of mucosal
eosinophilia. Although studies from the gut and other mucosal
organs suggest that eosinophils affect mucosal GI inflammation,
definitive roles for eosinophils in IBD await discovery. Figure 1
demonstrates the potential interactions of the eosinophil with the
intestinal mucosa and its resident cells.
Histological Characterization
To date, eosinophils are implicated in IBD because of their
morphological association with the diseased tissue. Early studies of
mucosal biopsies from patients with IBDs revealed that eosinophils
were prominent leukocytes infiltrating the intestinal epithelia (114–
117) (Fig. 1). Because of this initial observation, ulcerative colitis
(UC) and CD were sometimes described as allergic diseases (118).
A complicating factor in determining whether mucosal eosinophilia
is pathological is the fact that normal values for GI eosinophilia,
distal to the esophagus, have yet to be established. DeBrosse et al
(119) retrospectively characterized the quantity and distribution of
eosinophils in 28 children. They measured a wide variation from a
maximum of 26 eosinophils/hpf in the small intestine to up to 50
eosinophils/hpf in the proximal colon.
Accumulation of eosinophils in IBD has been characterized
in a number of histological studies; however, accuracy in true
reflection of the numbers and the contribution of eosinophils have
been hampered by various factors including use of nonspecific
staining, low sample numbers, sample acquisition, and choice of
patient population (120). Whereas some studies relied on hematox-
ylin and eosin staining for eosinophil identification, others were
powered with sample sizes as low as 2 per group in some instances.
In fact, recent evidence points to the importance of examination of
granular protein content in inflamed tissues because examination of
hematoxylin and eosin staining alone overlooks the contribution of
degranulated eosinophil products in diseased tissues (121). How-
ever, taken together, these studies indicate an increase in the
numbers of mucosal eosinophils in patients with IBD.
Recent studies characterized mucosal eosinophilia in the
colon and associated increased mucosal eosinophilia with IBD.
Pensabene et al evaluated the clinical significance of colonic
eosinophilia in 69 children seen during an 18-month period. Diag-
nostic categories included IBD (32%), irritable bowel syndrome
(33%), and food allergies (10%), with the remainder receiving a
wide range of other diagnoses. The distinguishing features for IBD
included high lamina propria cellularity and intracryptal/intrae-
pithelial eosinophils (122).
Secreted Eosinophil Products
Whereas some studies have characterized tissue eosinophilic
inflammation in IBD, others have focused on measuring secreted
products from eosinophils in the blood, tissue, intestinal lumen, and
fecal samples. Because it is well known that eosinophils secrete a
number of eosinophil-specific granule proteins such as ECP, EPO,
EDN, and MBP, increased levels of these products provide further
circumstantial support for their role in IBD. Peripheral eosinophils
from patients with active IBD have increased ECP release com-
pared with those with treated quiescent disease. These findings are
consistent with similar studies in asthma; patients treated with
prednisone have diminished ECP release and IL-5 expression
compared with those with active disease (123).
Ultrastructural studies demonstrate that eosinophils release
granule products in tissues with IBD. Some of the earliest studies in
this regard focus on electron microscopic studies of colonic resec-
tion specimens from patients with CD, which identified numerous
eosinophils, extracellular eosinophil MBP granule deposition,
and cytotoxic tissue changes (10,124). Other studies (125,126)
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examining mucosal biopsies from patients with CD reveal increased
eosinophils and ECP, and EPO deposition in visually inflamed and
normal areas of colon. Dubucquoi et al (127) showed increased
mucosal eosinophilia and IL-5 in the resected colon of patients with
CD requiring ileocolectomy. This increase in mucosal eosinophils
and IL-5 expression in the neoileum was associated with endo-
scopic recurrence of disease at surveillance endoscopy 3 months
later, suggesting that eosinophilia and local IL-5 production was
associated with early mucosal damage in CD.
Multiple groups have analyzed the concentration of EDGPs
in stool and correlated increased EDGP concentrations with severity
of disease. Berstad et al (128) first identified increased levels of
fecal ECP in stool samples from active ulcerative colitis (UC)
compared with normal, uninflamed controls. Bischoff et al (129)
later confirmed these findings in measurements of increased ECP
and EPX in stool samples from patients with UC, CD, and food
allergy compared with controls. They noted higher concentrations
of stool ECP and EPX in patients with evidence of gross mucosal
inflammation at endoscopy. Saitoh et al (130) found significantly
elevated concentrations of fecal levels of ECP and EPX in active
UC and CD compared with clinical and endoscopically inactive UC
and CD. Both inactive and active IBD had higher levels of ECP and
EPX compared with healthy controls. Also, inactive patients with
IBD with higher ECP and EPX fecal levels were more likely to
relapse in the following 3 months. Finally, Peterson et al (131)
studied fecal EPX levels in patients with UC with endoscopically
active disease before and after treatment. They determined that
fecal EPX decreased after corticosteroid treatments.
Colonic perfusion fluids from patients with intestinal inflam-
mation also contain increased levels of EDGPs compared with
controls. For example, Carlson et al (132) found elevated ECP,
EPO, and EPX in colonic perfusion fluids of patients with colitis
and isolated proctitis compared with healthy controls. They later
found that colonic perfusion levels of ECP, EPO, and EPX
decreased following steroid treatment (35). Sangfelt et al (35)
found that a reduction of EDGP levels in rectal perfusion fluid
was associated with successful response to prednisone treatment in
patients with EGIDs. Increased ECP levels in colonic perfusion
effluents in children with UC and CD (133) and adults with UC
(134) have also been described.
In contrast, Heatley and James (135) analyzed rectal biopsies
from patients with UC undergoing surveillance colonoscopy. They
found that patients with mild-to-moderate disease who had
responded to treatment had significantly raised tissue eosinophil
counts compared with patients with aggressive disease that did not
respond to treatment. The authors speculated that eosinophils may
have contributed to the positive clinical response. Similarly, Lam-
pinen et al (25) found increased eosinophil activation, as defined by
CD69 and CD44 staining, in UC in remission compared with active
UC, and suggested that eosinophils may contribute to repair of
injured epithelia. Finally, Troncone et al (133) found increased ECP
levels in gut lavage fluid in children with UC and CD, compared
with healthy controls, but ECP levels did not directly correlate with
clinical disease activity scores.
Raab et al (136) found a significant elevation in levels of the
lipid prostaglandin E2 (PGE2) in rectal and sigmoid perfusates in
patients with UC. Increased levels were associated with elevations
in ECP, MPO, and TNF-a levels. These mediators were colocalized
with eosinophils and macrophages, implicating these 2 cell types in
the synthesis of PGE2 in colitis. PGE2 has multiple functions
including potential roles in intestinal repair; further studies will
define the role of eosinophil-derived lipid mediators in protection
against or participation in mucosal injury in IBD (137).
Patients with active IBD present with significant elevation in
serum levels of eotaxin when compared with patients with quiescent
disease or normal controls, indicating a potential role for eotaxin and
its downstream targets in IBD activity (38,39). Other authors found
elevated levels of activated eosinophils in pediatric UC. This eosi-
nophilia was determined to positively correlate with disease severity
and predominantly resulted from eotaxin-1 production in rectosig-
moid colonic specimens (138). Eosinophil recruitment and activation
may play an important role in the chronicity of IBD in patients.
Taken together, these studies focus on microscopic evidence
of eosinophilia, eosinophil degranulation, cytokine production, and
increased eosinophil granule protein products in the stool and
colonic perfusion fluid of patients with severe UC or CD. They
suggest that the eosinophil is associated with IBD—in other words,
present and active at the site of inflammation.
Deleterious Impact of Eosinophil Products on
the GI Tract
Guilt by association is not enough to convict the eosinophil
as a participant in the pathogenesis of IBD. As described above, a
number of clinical and translational studies have shown that eosi-
nophils and their products are increased in tissues affected by IBD
and bathe mucosal surfaces at the sites of inflammation. Thus,
studies focusing on eosinophils and their products in reductionist
and genetically modified murine systems are beginning to tease out
the role of this leukocyte. In a reductionist noncontact, coculture
model system examining the impact of eosinophils on colonic
epithelial cells, eosinophil-derived products were shown to dimin-
ish epithelial barrier function as measured by transepithelial resist-
ance. The active soluble product derived from this coculture system
was identified as MBP, whereas EDN did not elicit the same impact
(139). Xu et al (15) demonstrated that sonicates from eosinophils
increase fibroblast proliferation and collagen production in fibro-
blasts outgrown from biopsies in active CD. A comparative study of
peripheral eosinophils between patients with CD and UC indicates
differences in chemotactic abilities, adhesion properties, and degra-
nulation activity between these patient subsets (140). Thus, the
eosinophil may indeed present in a variety of phenotypes depending
on the immune environment and associated disease mechanism.
Several animal models show the eosinophil’s impact as an
effector cell in models of IBD. For example, MBP null mice
exposed to oxazolone colitis were relatively protected from colitis
compared with wild-type mice, suggesting a role for MBP (139).
Forbes et al (141) also showed that in the murine model of DSS
colitis, mice have increased colonic eosinophilia, GI dysfunction,
and release of EPO into the colonic lumen. Eotaxin knockout mice
have decreased colonic eosinophilia, attenuated experimental UC,
and decreased levels of colonic EPO release (54,138). EPO-
deficient mice have attenuated experimental colitis, providing
further support for the eosinophil’s role (141). Shichijo et al
(142) examined EDGPs in a rat model of UC. Rats treated with
anti-ECP antibody develop attenuated DSS colitis, decreased ECP
staining, and improved epithelial healing compared with untreated
controls. Finally, Ahrens et al and Vieira et al (138,143) both have
shown that mice congenitally deficient in eosinophil development
are protected from experimental colitis.
SAMP1/Yit mice develop spontaneous ileitis in association
with increased IL-5 and eosinophil infiltration (144). Anti-IL-5
antibody treatment in a model where severe combined immunode-
ficiency mice are recipients of naı¨ve and effector CD4þ cells from
the SAMP1/Yit mouse leads to improvement of ileitis, colitis, and
eosinophil infiltration (144). In another study, when IL-5 knockout
mice, which have decreased eosinophils at a baseline, undergo
DSS colitis no changes in disease severity were seen compared
with wild-type controls (43). Thus, although human data remain
circumstantial, both cell culture and animal models are providing
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increasing evidence for a role for eosinophils and their granule
proteins in the pathogenesis of intestinal inflammation. A growing
body of literature now exists that examine specific roles of eosi-
nophilia in colitis in genetically engineered mice that are deficient
in eosinophil-specific granule proteins, eosinophils, or eosinophil
chemokines (eotaxin). Further basic and translational research into
the specific mechanisms by which eosinophils participate in intes-
tinal inflammation is still needed.
CONCLUSIONS
Circumstantial evidence places eosinophils at the scene of
inflammation. A growing body of basic evidence in other organs,
including the gut, implicates eosinophil products with tissue dys-
function. Is the eosinophil the purveyor of tissue damage? Is the
eosinophil, the innocent bystander, attacked in the fray along with
the intestinal epithelium? Was the eosinophil recruited for tissue
repair at the site of damage?
Considering the published literature that examines the gut as
well as other organs, it is reasonable to speculate a beneficial and
deleterious role for eosinophils in IBDs. Eosinophils are present in
healthy intestinal mucosa and increase during inflammation. They
possess an armamentarium of biologically active mediators that, in
the appropriate microenvironment, may help or harm the host.
Although the bulk of evidence supports a pathological role for
eosinophils in IBDs, recent microbial studies support a protective
role in states of sepsis. Reductionist in vitro experiments, relevant
animal models, and translational studies will continue to shed light
on this intriguing cell for many years to come.
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